The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients

<div>(a) Decision tree framework. (b) Results of cost-effectiveness analysis after roll-back calculation. EpoB: recombinant human erythropoietin beta, CERA: continuous erythropoietin receptor activator, CE ration: cost-effectiveness ratio.</div>

Anemia

fig3

Figure 3

Figure 3: The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients 

Figure 3 | The Cost-Effectiveness of Continuous Erythropoiesis Receptor Activator Once Monthly versus Epoetin Thrice Weekly for Anaemia Management in Chronic Haemodialysis Patients 